Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), retaining the price target of $6.00.
Rami Katkhuda has given his Buy rating due to a combination of factors surrounding VYNE Therapeutics. The company reported a solid financial position with $50.3 million in cash and marketable securities, which is projected to support operations until the second half of 2026. This financial stability provides a strong foundation for the company’s ongoing and future projects.
Furthermore, the promising developments in VYNE’s pipeline, particularly with their drug candidate Repibresib (VYN201), contribute to the positive outlook. The Phase IIb study for Repibresib is progressing well, with expectations for topline data by mid-2025. The drug has shown rapid and meaningful clinical benefits in earlier trials and offers potential advantages over existing treatments, such as once-daily administration and a favorable safety profile. These factors, combined with the potential for improved efficacy at higher concentrations, position VYNE Therapeutics as a compelling investment opportunity.
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 17.1% and a 39.63% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., VYNE Therapeutics, and Vera Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.